Giovanni D Di Minno

List of Publications by Year
in descending order

212 papers	7,574 citations	44069 48 h-index	69250 77 g-index

217 all docs	217 docs citations	217 times ranked	8257 citing authors

#	Article	IF	Citations
1	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. Seminars in Thrombosis and Hemostasis, 2022, 48, 100-108.	2.7	21
2	Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2022, 48, 124-126.	2.7	5
3	Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement. Blood Reviews, 2022, 51, 100885.	5.7	7
4	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
5	The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Reviews, 2021, 46, 100737.	5.7	7
6	Comparative analysis of the pivotal studies of extended halfâ€life recombinant FVIII products for treatment of haemophilia A. Haemophilia, 2021, 27, e422-e433.	2.1	14
7	Perspective â€“ The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Blood Reviews, 2021, 50, 100849.	5.7	4
8	Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Current Vascular Pharmacology, 2021, 19, 542-555.	1.7	11
9	Pain assessment and management in Italian Haemophilia Centres. Blood Transfusion, 2021, 19, 335-342.	0.4	8
10	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4925.	2.4	27
11	RASopathies and hemostatic abnormalities: key role of platelet dysfunction. Orphanet Journal of Rare Diseases, 2021, 16, 499.	2.7	5
12	Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.4	2
13	Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine. Blood Reviews, 2020, 39, 100618.	5.7	24
14	From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. Blood Reviews, 2020, 39, 100613.	5.7	16
15	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. Genes, 2020, 11, 1243.	2.4	5
16	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
17	Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Blood Transfusion, 2020, 18, 152-158.	0.4	8
18	Convalescent plasma for administration of passive antibodies against viral agents. Haematologica, 2020, 105, 2710-2715.	3.5	3

#	Article	IF	Citations
19	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. Minerva Medica, 2020, 111, 370-372.	0.9	0
20	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
21	Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. Blood Reviews, 2019, 33, 106-116.	5.7	12
22	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. Seminars in Thrombosis and Hemostasis, 2019, 45, 468-477.	2.7	19
23	Red Wine Consumption and Cardiovascular Health. Molecules, 2019, 24, 3626.	3.8	131
24	The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. TH Open, 2019, 03, e286-e294.	1.4	12
25	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	2.1	16
26	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. Internal and Emergency Medicine, 2019, 14, 447-449.	2.0	5
27	Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A . Patient Preference and Adherence, 2019, Volume 13, 233-240.	1.8	11
28	Commentary on: Borrini M, Garlaschelli L. A <scp>BPA</scp> Approach to the Shroud of Turin. J Forensic Sci 2019;64(1):137â€"43.. Journal of Forensic Sciences, 2019, 64, 325-326.	1.6	2
29	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. Mayo Clinic Proceedings, 2019, 94, 37-43.	3.0	17
30	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine, 2019, 14, 21-38.	2.0	13
31	Cytomegalovirus-Associated Splanchnic Vein Thrombosis in Immunocompetent Patients: Two Case Reports and Literature Review. Seminars in Thrombosis and Hemostasis, 2018, 44, 298-303.	2.7	3
32	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). Seminars in Thrombosis and Hemostasis, 2018, 44, 551-560.	2.7	12
33	Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. International Journal of Cardiology, 2018, 271, 366-370.	1.7	17
34	Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins. International Journal of Molecular Sciences, 2018, 19, 2350.	4.1	47
35	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. Annals of Medicine, 2017, 49, 329-342.	3.8	6
36	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44

#	Article	IF	Citations
37	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist, 2017, 22, 601-608.	3.7	108
38	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal of Hematology, 2017, 92, 646-652.	4.1	10
39	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. Internal and Emergency Medicine, 2017, 12, 425-435.	2.0	6
40	Glanzmannâ€™s thrombasthenia: strategies for identification and management. Expert Opinion on Orphan Drugs, 2017, 5, 641-653.	0.8	6
41	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. Annals of Hematology, 2017, 96, 1253-1270.	1.8	18
42	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia and Lymphoma, 2017, 58, 2633-2641.	1.3	19
43	Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. Haematologica, 2017, 102, 411-418.	3.5	14
44	Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. Seminars in Thrombosis and Hemostasis, 2017, 43, 069-074.	2.7	12
45	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Internal and Emergency Medicine, 2017, 12, 1291-1305.	2.0	23
46	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. European Journal of Haematology, 2017, 99, 306-314.	2.2	12
47	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. Journal of Immunology Research, 2017, 2017, 1-13.	2.2	29
48	New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfusion Medicine Reviews, 2016, 30, 92-99.	2.0	95
49	Blood stains of the Turin Shroud 2015: beyond personal hopes and limitations of techniques. Internal and Emergency Medicine, 2016, 11, 507-516.	2.0	4
50	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Reviews, 2016, 30, 35-48.	5.7	34
51	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfusion, 2016, 14, 255-61.	0.4	21
52	The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica, 2015, 100, 1038-44.	3.5	53
53	Novel oral anticoagulants in atrial fibrillation. Journal of Cardiovascular Medicine, 2015, 16, 512-519.	1.5	10
54	Acquired Hemophilia A successfully treated with rituximab. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015024.	1.3	4

#	Article	IF	Citations
55	Prophylaxis of venous thromboembolism in elderly patients with multi-morbidity: the REPOSI data. Internal and Emergency Medicine, 2015, 10, 251-252.	2.0	0
56	Methylation Reactions, the Redox Balance and Atherothrombosis: The Search for a Link with Hydrogen Sulfide. Seminars in Thrombosis and Hemostasis, 2015, 41, 423-432.	2.7	7
57	Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders. Blood Reviews, 2015, 29, S26-S33.	5.7	10
58	Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?. Seminars in Thrombosis and Hemostasis, 2015, 41, 382-388.	2.7	54
59	Laboratory tests during direct oral anticoagulant treatment? Authorsâ€™ reply. Internal and Emergency Medicine, 2015, 10, 533-534.	2.0	1
60	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. Blood Reviews, 2015, 29, 335-343.	5.7	24
61	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thrombosis Research, 2015, 135, 923-932.	1.7	78
62	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. Seminars in Thrombosis and Hemostasis, 2015, 41, 113-132.	2.7	7
63	The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica, 2015, 100, 1031-7.	3.5	43
64	Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. Thrombosis Research, 2015, 136, 1074-1081.	1.7	25
65	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. Journal of Clinical Investigation, 2015, 125, 3766-3781.	8.2	39
66	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
67	Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. Blood Transfusion, 2015, 13, 328-32.	0.4	3
68	A prospective study on survival in cancer patients with and without venous thromboembolism. Internal and Emergency Medicine, 2014, 9, 559-67.	2.0	27
69	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of Medicine, 2014, 46, 475-489.	3.8	15
70	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2478-2485.	2.4	48
71	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
72	Anticoagulant Therapy in Oncologic Patients Undergoing Venous Stenting for Superior Vena Cava Syndrome and Other Interventional Procedures. CardioVascular and Interventional Radiology, 2014, 37, 1401-1402.	2.0	5

#	Article	IF	Citations
73	Ensuring medication adherence with direct oral anticoagulant drugs. Thrombosis Research, 2014, 133, 699-704.	1.7	39
74	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. Thrombosis Research, 2014, 134, 264-267.	1.7	12
75	Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thrombosis and Haemostasis, 2014, 112, 424-425.	3.4	13
76	HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfusion, 2014, 12, 114-8.	0.4	14
77	Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfusion, 2014, 12 Suppl 1, s337-42.	0.4	12
78	Current and evolving features in the clinical management of haemophilia. Blood Transfusion, 2014, 12 Suppl 3, s554-62.	0.4	4
79	Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders. Blood Transfusion, 2014, 12 Suppl 3, s582-8.	0.4	2
80	Laboratory tests during direct oral anticoagulant treatment? No. Internal and Emergency Medicine, 2013, 8, 367-370.	2.0	14
81	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15812-15817.	7.1	52
82	Human genome, environment and medical practice. Internal and Emergency Medicine, 2013, 8, 645-649.	2.0	3
83	Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care and Research, 2013, 65, 141-147.	3.4	144
84	Management of patients with longâ€term inhibitors: is immune tolerance an underestimated lifeâ€long solution?. Haemophilia, 2013, 19, 18-23.	2.1	15
85	Improving the use of direct oral anticoagulants in atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 288-294.	2.2	11
86	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. Seminars in Thrombosis and Hemostasis, 2013, 39, 779-793.	2.7	12
87	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. Seminars in Thrombosis and Hemostasis, 2013, 39, 973-973.	2.7	1
88	Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature. Seminars in Thrombosis and Hemostasis, 2013, 39, 723-731.	2.7	53
89	Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C (and Congenital) Tj ETQq1 1 0.784314 rgBT /Overlock 1	2.7	5
90	Prenatal diagnosis of haemophilia: our experience of 44 cases. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2233-2238.	2.3	8

#	Article	IF	Citations
91	Magnetic resonance imaging and ultrasound evaluation of â€œhealthyâ€•joints in young subjects with severe haemophilia A. Haemophilia, 2013, 19, e167-73.	2.1	60
92	Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thrombosis and Haemostasis, 2013, 109, 1170-1179.	3.4	188
93	Replacement therapy for bleeding episodes in factor VII deficiency. Thrombosis and Haemostasis, 2013, 109, 238-247.	3.4	48
94	Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica, 2013, 98, 1495-1498.	3.5	20
95	Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica, 2013, 98, 538-544.	3.5	82
96	The role of the metabolic syndrome in patients with provoked venous thromboembolic events. Thrombosis and Haemostasis, 2013, 109, 759-761.	3.4	6
97	Clinical use of factor VIII and factor IX concentrates. Blood Transfusion, 2013, 11 Suppl 4, s55-63.	0.4	16
98	Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. Blood Transfusion, 2013, 11 Suppl 4, s101-9.	0.4	5
99	Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-Î± Blockers. Journal of Rheumatology, 2012, 39, 1042-1046.	2.0	38
100	Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 497-505.	2.7	46
101	The Infectious Burden in Atherothrombosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 515-523.	2.7	39
102	Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor-Î± Blockers. Journal of Rheumatology, 2012, 39, 568-573.	2.0	48
103	Filling the gap between science & clinical practice: Prevention of stroke recurrence. Thrombosis Research, 2012, 129, 3-8.	1.7	14
104	Platelet Reactivity and Disease Activity in Subjects with Psoriatic Arthritis. Journal of Rheumatology, 2012, 39, 334-336.	2.0	32
105	Urinary excretion of iPF2Î±-III predicts the risk of future thrombotic events. A 10-year follow-up. Thrombosis Research, 2012, 129, 208-211.	1.7	7
106	Aspirin Resistance, Platelet Turnover, and Diabetic Angiopathy: A 2011 Update. Thrombosis Research, 2012, 129, 341-344.	1.7	30
107	TNF-Î± blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Internal and Emergency Medicine, 2012, 7, 97-98.	2.0	14
108	Upper tract urothelial cell carcinoma presenting as fever of unknown origin and acid-sterile pyuria. Internal and Emergency Medicine, 2012, 7, 117-118.	2.0	2

#	Article	IF	Citations
109	Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. Thrombosis and Haemostasis, 2012, 107, 673-680.	3.4	20
110	Efficacy and safety of prophylaxis with once-weekly BAY 79â€“4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. Thrombosis and Haemostasis, 2012, 108, 913-922.	3.4	28
111	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia, 2012, 18, e173-87.	2.1	88
112	Longâ€term outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 2012, 10, 1297-1302.	3.8	129
113	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Internal and Emergency Medicine, 2012, 7, 9-13.	2.0	32
114	Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Annals of Medicine, 2011, 43, 531-544.	3.8	37
115	Genotype-independent in vivo oxidative stress following a methionine loading test: Maximal platelet activation in subjects with early-onset thrombosis. Thrombosis Research, 2011, 128, e43-e48.	1.7	14
116	Aspirin resistance and platelet turnover: A 25-year old issue. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 542-545.	2.6	19
117	New Anti-Thrombotic Drugs for Stroke Prevention. Current Vascular Pharmacology, 2011, 9, 723-732.	1.7	9
118	Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. Clinical Rheumatology, 2011, 30, 915-919.	2.2	5
119	Alcohol Dosing and the Heart: Updating Clinical Evidence. Seminars in Thrombosis and Hemostasis, 2011, 37, 875-884.	2.7	9
120	The Challenge of Diagnosing Pulmonary Embolism in Children, Pregnant Women, and Elderly Patients: A Descriptive Review of the Literature. Seminars in Thrombosis and Hemostasis, 2011, 37, 908-917.	2.7	4
121	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. Seminars in Thrombosis and Hemostasis, 2011, 37, 267-274.	2.7	44
122	Carotid Intima-Media Thickness in Psoriatic Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 705-712.	2.4	111
123	A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?. Blood Transfusion, 2011, 9 Suppl 2, s14-20.	0.4	3
124	Cost of care of haemophilia with inhibitors. Haemophilia, 2010, 16, e190-201.	2.1	66
125	Homocysteine and arterial thrombosis: Challenge and opportunity. Thrombosis and Haemostasis, 2010, 103, 942-961.	3.4	77
126	Acute coronary syndrome and severe haemophilia: An unusual association with challenging treatment. Thrombosis and Haemostasis, 2010, 103, 1270-1272.	3.4	13

#	Article	IF	Citations
127	Exploring newer cardioprotective strategies: Ï‰-3 fatty acids in perspective. Thrombosis and Haemostasis, 2010, 104, 664-680.	3.4	26
128	Mesoglycan: Clinical Evidences for Use in Vascular Diseases. International Journal of Vascular Medicine, 2010, 2010, 1-8.	1.0	23
129	Acquired Haemophilia A in the Elderly: Case Reports. Current Gerontology and Geriatrics Research, 2010, 2010, 1-5.	1.6	19
130	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World Journal of Gastroenterology, 2010, 16, 6119.	3.3	57
131	Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 217-223.	2.6	10
132	Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy. Thrombosis Research, 2010, 126, e434-e438.	1.7	14
133	Glanzmannâ€™s thrombasthenia (defective platelet integrin Î±IIb-Î²3): proposals for management between evidence and open issues. Thrombosis and Haemostasis, 2009, 102, 1157-1164.	3.4	57
134	Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2009, 35, 683-694.	2.7	75
135	Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetologica, 2009, 46, 253-261.	2.5	37
136	Perioperative handling of patients on antiplatelet therapy with need for surgery. Internal and Emergency Medicine, 2009, 4, 279-288.	2.0	74
137	FactorÂVIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophiliaAA patients with highâ€responding inhibitors. Journal of Thrombosis and Haemostasis, 2009, 7, 1809-1815.	3.8	103
138	Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. Thrombosis Research, 2009, 124, 711-713.	1.7	9
139	Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.. Blood, 2009, 114, 1290-1290.	1.4	0
140	Increased troponin I predicts in-hospital occurrence of hemodynamic instability in patients with sub-massive or non-massive pulmonary embolism independent to clinical, echocardiographic and laboratory information. International Journal of Cardiology, 2008, 124, 351-357.	1.7	37
141	Right-to-left shunt, atrial septal aneurysm and thrombophilia in patients with cryptogenic stroke or TIA vs. those with venous thrombo-embolism. International Journal of Cardiology, 2008, 130, 99-102.	1.7	4
142	Preclinical and prognostically relevant cardiovascular disease burden in systemic lupus erythematosus with low clinical damage index. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, e23-e25.	2.6	2
143	Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: Insights from echocardiography and exercise cardiac performance evaluation. Diabetes Research and Clinical Practice, 2008, 79, 262-268.	2.8	43
144	Haemophilia A: molecular insights. Clinical Chemistry and Laboratory Medicine, 2007, 45, 450-61.	2.3	47

#	Article	IF	Citations
145	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2250-2257.	2.4	65
146	Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagulation and Fibrinolysis, 2007, 18, 199-201.	1.0	14
147	Knowledge of cardiovascular risk factors and awareness of non-pharmacological approach for risk prevention in young survivors of acute myocardial infarction. The cardiovascular risk prevention project â€œHelp Your Heart Stay Youngâ€• Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 468-472.	2.6	8
148	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. European Journal of Clinical Investigation, 2007, 37, 48-53.	3.4	42
149	Glanzmannâ€™s Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents. Seminars in Hematology, 2006, 43, S33-S36.	3.4	37
150	Left Ventricular Chamber and Myocardial Systolic Function Reserve in Patients with Type 1 Diabetes Mellitus: Insight from Traditional and Doppler Tissue Imaging Echocardiography. Journal of the American Society of Echocardiography, 2006, 19, 848-856.	2.8	20
151	Adverse outcome in women with thrombophilia and bilateral uterine artery notches. Fertility and Sterility, 2006, 86, 726-727.	1.0	5
152	Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus. Thrombosis and Haemostasis, 2006, 95, 1033-1034.	3.4	12
153	A new method for determination of plasma homocystine by isotope dilution and electrospray tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 842, 64-69.	2.3	12
154	Insight into the nature of the CRPâ€“coronary event association using Mendelian randomization. International Journal of Epidemiology, 2006, 35, 922-931.	1.9	159
155	The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. Journal of Thrombosis and Haemostasis, 2005, 3, 1459-1466.	3.8	81
156	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. British Journal of Haematology, 2005, 131, 100-108.	2.5	17
157	EPCR Ser219Gly: Elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis, 2005, 183, 283-292.	0.8	56
158	Aspirin resistance and diabetic angiopathy: back to the future. Thrombosis Research, 2004, 113, 97-99.	1.7	18
159	Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism: Clinical and Experimental, 2004, 53, 852-857.	3.4	137
160	Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. Thrombosis and Haemostasis, 2004, 92, 1122-1128.	3.4	42
161	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2322-2329.	3.8	52
162	Denaturing HPLC Procedure for Factor IX Gene Scanning. Clinical Chemistry, 2003, 49, 815-818.	3.2	19

#	Article	IF	Citations
163	Haemophilia B: From Molecular Diagnosis to Gene Therapy. Clinical Chemistry and Laboratory Medicine, 2003, 41, 445-51.	2.3	18
164	Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. Journal of Hypertension, 2003, 21, 1415-1423.	0.5	55
165	Polyunsaturated fatty acids, thrombosis and vascular disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 361-364.	0.3	12
166	Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke. Stroke, 2002, 33, 51-56.	2.0	112
167	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 867-873.	2.4	137
168	Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertility and Sterility, 2002, 78, 371-375.	1.0	90
169	Glanzmannâ€™s Thrombasthenia: Identification of 19 New Mutations in 30 Patients. Thrombosis and Haemostasis, 2002, 87, 1034-1042.	3.4	62
170	Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. Haematologica, 2002, 87, 177-81.	3.5	26
171	Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thrombosis and Haemostasis, 2002, 87, 1034-42.	3.4	14
172	Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. Haematologica, 2002, 87, 1118-9.	3.5	7
173	Severe pancytopenia and intrahepatic cholestasis in a patient with a history of Hodgkinâ€™s disease.. European Journal of Internal Medicine, 2001, 12, 515-517.	2.2	0
174	Coexistence of Thrombophilic Gene Polymorphisms Among 559 Unrelated Consecutive Patients With a History of Thrombosis. Thrombosis Research, 2001, 101, 317-319.	1.7	2
175	Fibrinogen Naples I (BÎ² A68T) Nonsubstrate Thrombin-Binding Capacities. Thrombosis Research, 2001, 103, 63-73.	1.7	42
176	Plasma Folate, Vitamin B₁₂, and Total Homocysteine and Homozygosity for the C677T Mutation of the 5,10-Methylene Tetrahydrofolate Reductase Gene in Patients with Alzheimerâ€™s Dementia. Gerontology, 2001, 47, 324-329.	2.8	81
177	Inherited Thrombophilic Risk Factors and Venous Thromboembolism. Chest, 2000, 118, 1405-1411.	0.8	79
178	Homocysteine, Coagulation, Platelet Function, and Thrombosis. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 243-254.	2.7	131
179	C-Reactive Protein in Offspring Is Associated With the Occurrence of Myocardial Infarction in First-Degree Relatives. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 198-203.	2.4	49
180	Idiopathic Buddâ€“Chiari syndrome in a patient with homozygous Factor V Leiden and heterozygous Factor II G20210A mutations. Thrombosis Research, 2000, 100, 567-568.	1.7	3

#	Article	IF	Citations
181	Persistent Impairment of Platelet Aggregation following Cessation of a Short-course Dietary Supplementation of Moderate Amounts of N-3 Fatty Acid Ethyl Esters. Thrombosis and Haemostasis, 1999, 82, 128-133.	3.4	26
182	Inherited Prothrombotic Conditions and Premature Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1751-1756.	2.4	113
183	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1368-1377.	2.4	287
184	Anticardiolipin Antibodies in Patients With Liver Disease. American Journal of Gastroenterology, 1999, 94, 2983-2987.	0.4	78
185	Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. American Journal of Cardiology, 1999, 83, 1196-1200.	1.6	38
186	The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commercial Confirmatory System Tests. Thrombosis Research, 1999, 94, 373-380.	1.7	6
187	Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. American Journal of Obstetrics and Gynecology, 1998, 179, 1324-1328.	1.3	168
188	Identifying human platelet glycoproteins IIb and IIIa by capillary electrophoresis. Electrophoresis, 1998, 19, 1468-1474.	2.4	5
189	PAI-1 Plasma Levels in a General Population Without Clinical Evidence of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 562-567.	2.4	140
190	A Fast and Accurate Method for Genotyping the Angiotensin-Converting Enzyme I/D Polymorphism. Circulation, 1998, 97, 1213-1214.	1.6	10
191	Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke. Stroke, 1998, 29, 399-403.	2.0	80
192	Homozygous C677T Mutation of the 5,10 Methylenetetrahydrofolate Reductase Gene and Hyperhomocysteinemia in Italian Patients With a History of Early-Onset Ischemic Stroke. Stroke, 1998, 29, 869-871.	2.0	40
193	The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 152-156.	2.4	128
194	Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. Journal of Hypertension, 1998, 16, 985-991.	0.5	11
195	Endothelin Abnormalities in Patients With Pulmonary Embolism. Chest, 1997, 111, 544-549.	0.8	37
196	Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2082-2087.	2.4	69
197	High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia, 1997, 40, 1191-1196.	6.3	69
198	Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?. Cardiovascular Drugs and Therapy, 1997, 10, 743-749.	2.6	2

#	Article	IF	Citations
199	Deletion Polymorphism in the Angiotensin-Converting Enzyme Gene in Patients With a History of Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 304-309.	2.4	68
200	Fibrinolytic, platelet and monocyte variables in homozygous familial hypercholesterolemia. The effect of a regular plasma cholesterol removal by LDL-apheresis. Fibrinolysis, 1993, 7, 63-64.	0.5	6
201	Drugs affecting plasma fibrinogen levels. Cardiovascular Drugs and Therapy, 1992, 6, 25-27.	2.6	24
202	Searching for the thrombogenic mechanism(s) of fibrinogen. Thrombosis Research, 1990, 57, 61-67.	1.7	5
203	Newer agents for coronary thrombolysis. Perspectives from clinical studies. Pharmacological Research, 1989, 21, 153-161.	7.1	7
204	Aspirin as an antithrombotic agent. , 1989, 33, 43-62.		0
205	The Causal Role of Salt Depletion in Acute Renal Failure Due to Captopril in Hypertensive Patients with a Single Functioning Kidney and Renal Artery Stenosis. Renal Failure, 1987, 10, 9-20.	2.1	20
206	Effects of PGE₂ Infusion on Renal Function in Normal Man before and after Angiotensin II Inhibition by Captopril. Kidney and Blood Pressure Research, 1987, 10, 289-296.	2.0	0
207	Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. American Journal of Medicine, 1985, 79, 552-559.	1.5	228
208	Arachidonic acid induces human platelet-fibrin retraction: The role of platelet cyclic endoperoxides. Thrombosis Research, 1982, 25, 299-306.	1.7	3
209	Increased PGI2 activity in venous tissues from rats on oral contraceptives is not prevented by heparin administration before vessel isolation. Thrombosis Research, 1980, 18, 895-896.	1.7	3
210	Plasmatic and vascular factors of the hemostatic system in rats receiving an estrogen-progestogen combination. Contraception, 1980, 22, 249-257.	1.5	2
211	Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an destrogen-progestagen combination. Thrombosis Research, 1979, 14, 793-797.	1.7	34
212	DIPYRIDAMOLE AND PLATELET FUNCTION. Lancet, The, 1978, 312, 1257-1259.	13.7	14